Kelonia Therapeutics, Inc.

Kevin M Friedman

Molly R Perkins

Andrew Avery

Cory Ahonen

Stephen L Sazinsky

Emily Thompson Beura

Connor S Dobson

Shannon G Contrastano

The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more chimeric antigen receptors to immune effector cells in vivo.

Compositions for treating cancer

The present disclosure provides compositions comprising antigen binding polypeptides. More particularly, the disclosure relates to polypeptides comprising antibodies or antigen binding fragments thereof, nucleic acids encoding the polypeptides, and vectors for expressing the same.

Antigen binding polypeptides

Provided herein are lentiviral vectors comprising a mutated, heterologous envelope protein, a targeting protein, and at least one transgene for delivery to and expression by a cell characterized by the targeting protein. Also provided are methods and materials for producing the lentiviral vectors described herein, methods for transducing target cells, and cells transduced by lentiviral vectors according to the present disclosure.

Lymphocyte targeted lentiviral vectors

Growing community of inventors

Boston, MA, United States of America

Kevin M Friedman